🇺🇸 MPDL3280A in United States

63 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Febrile Neutropenia — 9 reports (14.29%)
  2. Pneumonia — 8 reports (12.7%)
  3. Anaemia — 6 reports (9.52%)
  4. Aspartate Aminotransferase Increased — 6 reports (9.52%)
  5. Diarrhoea — 6 reports (9.52%)
  6. Dyspnoea — 6 reports (9.52%)
  7. Neutropenia — 6 reports (9.52%)
  8. Neutrophil Count Decreased — 6 reports (9.52%)
  9. Nausea — 5 reports (7.94%)
  10. White Blood Cell Count Decreased — 5 reports (7.94%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is MPDL3280A approved in United States?

MPDL3280A does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for MPDL3280A in United States?

Clovis Oncology, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.